Business Context and Reporting Period
Company: Alnylam Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Report Date: September 10, 2025
Event Date: September 8, 2025
Context: The filing reports the commencement and subsequent pricing of a proposed offering of convertible senior notes due 2028 to qualified institutional buyers pursuant to Rule 144A.
Key Financial Metrics
This Form 8-K does not contain audited financial statements, revenue, profit, cash flow, margin, or liquidity data. The filing focuses exclusively on the capital markets transaction described below.
- Instrument: Convertible Senior Notes due 2028.
- Offering Status: Commenced on September 8, 2025; priced on September 9, 2025.
- Target Investors: Qualified Institutional Buyers (Rule 144A).
Material Changes
The material change reported is the initiation of a new debt financing vehicle. Specific terms regarding the principal amount, interest rate, conversion price, or total proceeds are not detailed in the text of this 8-K; they are referenced in the attached press releases (Exhibits 99.1 and 99.2).
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates by reference press releases issued on September 8 and September 9, 2025, regarding the offering details.
Risks and Contingencies: The filing includes a standard disclaimer stating that the report and its exhibits do not constitute an offer to sell or a solicitation of an offer to buy securities in any jurisdiction where such an offer would be unlawful.
Investor Verification Checklist
- Review Exhibit 99.1 (September 8 press release) for the initial offering structure.
- Review Exhibit 99.2 (September 9 press release) for the final pricing terms, including interest rate, conversion ratio, and total aggregate principal amount.
- Verify the impact of the new convertible debt on the company's existing capital structure and potential dilution.
- Confirm the intended use of proceeds as detailed in the referenced press releases.